Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $54.94.

Several equities research analysts have recently weighed in on NTLA shares. Barclays decreased their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Robert W. Baird lowered their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company cut their price target on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, November 18th. Citigroup dropped their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Oppenheimer reduced their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 11th.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $13.13 on Wednesday. The stock’s 50-day moving average is $16.04 and its two-hundred day moving average is $20.53. Intellia Therapeutics has a 1 year low of $12.47 and a 1 year high of $34.87. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -2.41 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.38) EPS. As a group, research analysts predict that Intellia Therapeutics will post -5.12 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares in the last quarter. State Street Corp grew its stake in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the period. Geode Capital Management LLC raised its holdings in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after acquiring an additional 49,367 shares during the last quarter. FMR LLC lifted its stake in shares of Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after purchasing an additional 111,104 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in shares of Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.